Form D · Biotechnology
Avalo, Inc.
Durham, NC · CIK 0001875179
Offering snapshot reported Feb 7, 2022 · SEC filing
- Reported sold
- $500K Offering amount: $1.1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 7, 2022 | Initial | $500,000 | No comparison | 2 | SEC filing |
| Jul 27, 2021 | Initial | $2,900,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-432631
Source: Form D, filed Feb 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mariano Alvarez | Director, Executive, Promoter |
| Brendan Collins | Director, Executive, Promoter |
| Laurie Menoud | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1501 Hollywood Street
Durham, NC, 27701
Durham, NC, 27701